Sectors:
Locations:
Min Investment:
Max Investment:
Target Investment:
2023
2023
“Powered by Advanced and Clinically Tested Bioprinting Technologies” Our lead product is 3DMatrix™, a 3D-printed monofilament bioresorbable surgical mesh has received FDA 510(k) clearance.
2021
Applying high throughput DNA encoded library (DEL) drug screening technologies in novel ways to deliver therapeutics that address the most difficult problems in clinical medicine
2019
Using advanced, proprietary technologies to develop novel therapeutics targeting the fundamental mechanisms of aging. Its lead programs utilize proprietary, state-of-the-art biotechnology platforms to restore the youthful balance of aged or “senescent” and young cells in the skin, targeting the senescent cells for elimination. This provides a “reboot” of one’s genetic program to turn the clock on one’s skin back to its youthful exuberance.
2018
Identifying potentially disruptive biopharmaceutical companies within a sea of less compelling opportunities
2020
2022
Conquering the Last Frontier in Patient Monitoring. FIZE® Medical offers the first platform technology to remotely monitor and manage patients with an indwelling Foley catheter, providing unprecedented safety to both patients and their caregivers.
2020 - 2022
2021
2021
Physicians, founders, executives and investors working to expand the entrepreneurial healthcare ecosystem in Miami
2021
2021
Building a Best-in-class Urologic Oncology Company. Developing technologies to better visualize and treat urologic cancers through minimally invasive procedures in the physicians’ office
2021
2021
Enabling promising early-stage life science companies to develop the next generation of innovative therapies to improve the lives of patients. We want to do this by offering them Contract Research Organization (CRO) Services, newly renovated wet-lab space, process and analytical development support, short-term financing, and third-party due diligence validation, among other services.
2020
2020